Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9HC98

UPID:
NEK6_HUMAN

ALTERNATIVE NAMES:
Never in mitosis A-related kinase 6; Protein kinase SID6-1512

ALTERNATIVE UPACC:
Q9HC98; B7Z2D9; Q5TBG3; Q5TBG9; Q6FG86; Q6IAR3; Q96E83; Q9ULX2

BACKGROUND:
The protein kinase SID6-1512, or Serine/threonine-protein kinase Nek6, is crucial for mitotic progression, facilitating robust mitotic spindle formation and successful cytokinesis. It phosphorylates key proteins such as KIF11, enhancing spindle assembly, and is involved in G2/M phase arrest following DNA damage. Nek6's activity in phosphorylating EML4 for chromosome congression underscores its critical role in maintaining genomic stability.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine/threonine-protein kinase Nek6 offers a promising avenue for drug discovery. Its ability to suppress cancer cell senescence through p53/TP53 pathways and its essential role in cell cycle progression make it a potential target for therapeutic intervention in cancer treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.